Cereno Scientific’s CS585 program is granted patent in the US
Cereno Scientific (XSAT: CRNO B) today announced that the first patent in the company’s preclinical CS585 program has been granted by the US Patent Office (USPTO). The CS585 program is currently undergoing a 2-year preclinical development program in collaboration with the University of Michigan with the aim of a successful transition to a Phase I clinical program. The program comprises prostacyclin receptor agonists that have demonstrated potential to significantly improve on mechanisms relevant to selected cardiovascular diseases.“It is very positive that the first patent has been obtained